Similar articles for PMID: 34732448

Year	Number of Results
2004	1
2006	2
2007	1
2010	1
2011	2
2013	9
2014	8
2015	11
2016	13
2017	8
2018	9
2019	13
2020	18
2021	26
2022	12
2023	13

1

Survival Prediction by Baseline Systemic Immune-inflammation Index (SII) and its Changes During First-line Platinum-based Treatment in a Caucasian Population of Patients With Metastatic Urothelial Carcinoma (MUC).

Palacka P, Slopovsky J, Obertova J, Chovanec M, Rejlekova K, Sycova-Mila Z, Kollarik B, Mardiak J, Mego M. Palacka P, et al. Anticancer Res. 2021 Nov;41(11):5749-5759. doi: 10.21873/anticanres.15391. Anticancer Res. 2021. PMID: 34732448

2

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.

Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Fléchon A, Gunduz S, Loriot Y, Rodriguez-Vida A, Mamtani R, Yu EY, Nam K, Imai K, Homet Moreno B, Alva A; KEYNOTE-361 Investigators. Powles T, et al. Lancet Oncol. 2021 Jul;22(7):931-945. doi: 10.1016/S1470-2045(21)00152-2. Epub 2021 May 26. Lancet Oncol. 2021. PMID: 34051178 Clinical Trial.

3

Comparative Study of the Safety and Efficacy of First-Line Cisplatin and Carboplatin Chemotherapy in Elderly Patients with Metastatic Urothelial Carcinoma.

Huang SY, Wu CC, Hsieh MC, Rau KM, Chiang PH, Sung MT, Luo HL, Huang CC, Huang CH, Liu JM, Su HY. Huang SY, et al. Oncology. 2020;98(3):146-153. doi: 10.1159/000504393. Epub 2019 Dec 3. Oncology. 2020. PMID: 31794969

4

First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.

Mori K, Pradere B, Moschini M, Mostafaei H, Laukhtina E, Schuettfort VM, Sari Motlagh R, Soria F, Teoh JYC, Egawa S, Powles T, Shariat SF; European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU). Mori K, et al. Eur J Cancer. 2021 Jul;151:35-48. doi: 10.1016/j.ejca.2021.03.049. Epub 2021 May 4. Eur J Cancer. 2021. PMID: 33962359 Free article.

5

The predictive value of a preoperative systemic immune-inflammation index and prognostic nutritional index in patients with esophageal squamous cell carcinoma.

Zhang H, Shang X, Ren P, Gong L, Ahmed A, Ma Z, Ma R, Wu X, Xiao X, Jiang H, Tang P, Yu Z. Zhang H, et al. J Cell Physiol. 2019 Feb;234(2):1794-1802. doi: 10.1002/jcp.27052. Epub 2018 Aug 2. J Cell Physiol. 2019. PMID: 30070689

6

[Treatment and prognosis of 117 patients with advanced urothelial carcinoma of the bladder].

Song Y, Yang L, Zhou A, Chi Y, Wang J. Song Y, et al. Zhonghua Zhong Liu Za Zhi. 2014 Mar;36(3):212-6. Zhonghua Zhong Liu Za Zhi. 2014. PMID: 24785283 Chinese.

7

Response to Platinum-based Chemotherapy Rechallenge for Patients With Pembrolizumab-refractory Urothelial Carcinoma.

Yumioka T, Honda M, Shimizu R, Teraoka S, Yamaguchi N, Kawamoto B, Iwamoto H, Morizane S, Hikita K, Takenaka A. Yumioka T, et al. Anticancer Res. 2021 Nov;41(11):5767-5773. doi: 10.21873/anticanres.15393. Anticancer Res. 2021. PMID: 34732450

8

Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.

Hahn NM, Stadler WM, Zon RT, Waterhouse D, Picus J, Nattam S, Johnson CS, Perkins SM, Waddell MJ, Sweeney CJ; Hoosier Oncology Group. Hahn NM, et al. J Clin Oncol. 2011 Apr 20;29(12):1525-30. doi: 10.1200/JCO.2010.31.6067. Epub 2011 Mar 21. J Clin Oncol. 2011. PMID: 21422406 Clinical Trial.

9

The Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy.

Zhang Y, Chen Z, Jin F, Guo D, Chen Q, Liu Z, Ji S, Gao G. Zhang Y, et al. Mediators Inflamm. 2021 Oct 29;2021:2910892. doi: 10.1155/2021/2910892. eCollection 2021. Mediators Inflamm. 2021. PMID: 34744510 Free PMC article.

10

Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.

Liu J, Li S, Zhang S, Liu Y, Ma L, Zhu J, Xin Y, Wang Y, Yang C, Cheng Y. Liu J, et al. J Clin Lab Anal. 2019 Oct;33(8):e22964. doi: 10.1002/jcla.22964. Epub 2019 Jul 8. J Clin Lab Anal. 2019. PMID: 31282096 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

117 results

Results by year